In this third installment, Dr Moore shares insights from the TRADE study, which evaluated a dose-escalation strategy for abemaciclib in patients with HR-positive, HER2-negative, high-risk breast cancer. Dr Moore emphasizes the importance of combining TRADE study findings with real-world evidence to refine dose-escalation strategies and improve patient outcomes.
